help button home button Am J Pathol Epitomics Buy 2 Antibodies Get 1 Free Special Offer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kosugi, T.
Right arrow Articles by Kadomatsu, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kosugi, T.
Right arrow Articles by Kadomatsu, K.
(American Journal of Pathology. 2006;168:9-19.)
© 2006 American Society for Investigative Pathology

Growth Factor Midkine Is Involved in the Pathogenesis of Diabetic Nephropathy

Tomoki Kosugi*{dagger}, Yukio Yuzawa{dagger}, Waichi Sato{dagger}, Hanayo Kawai*{dagger}, Seiichi Matsuo{dagger}, Yoshifumi Takei*, Takashi Muramatsu{ddagger} and Kenji Kadomatsu*

From the Departments of Biochemistry* and Clinical Immunology of Internal Medicine,{dagger} Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan; and Department of Health Science,{ddagger} Faculty of Psychological and Physical Sciences, Aichi Gakuin University, Nisshin, Japan


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
Diabetic nephropathy is a life-threatening disease associated with diabetes mellitus. Longstanding hyperglycemia induces pathological reactions of glomerular mesangial cells, such as overproduction of extracellular matrix, which finally lead to nephropathy. However, the mechanisms underlying its pathogenesis have not been completely elucidated. Using the Streptozotocin-induced model of diabetes, we report that mice deficient in the growth factor midkine (Mdk–/–) exhibited strikingly milder nephropathy than Mdk+/+ mice, even though both mice showed similar extents of hyperglycemia after Streptozotocin injection. Midkine expression was induced in the glomerular mesangium of Mdk+/+ mice with diabetic nephropathy and in primary cultured mesangial cells exposed to high glucose. Mdk–/– mesangial cells exhibited reduced phosphorylation of protein kinase C and extracellular signal-regulated kinase as well as reduced production of transforming growth factor-ß1 on high glucose loading. Addition of exogenous midkine restored extracellular signal-regulated kinase phosphorylation in Mdk–/– cells under high glucose conditions, whereas a midkine antisense oligodeoxynucleotide suppressed midkine in Mdk+/+ cells. Therefore, this study identifies midkine as a key molecule in diabetic nephropathy and suggests that midkine accelerates the intracellular signaling network evoked by hyperglycemia in nephropathy.

Diabetic nephropathy is a major complication of diabetes mellitus, which is the most common cause of end-stage renal failure in many countries.1,2 Therefore, it is very important for the development of therapeutic strategies to elucidate the molecular mechanism underlying this disease. There is an increasing body of evidence that the pathogenesis involves many molecules, such as protein kinase C (PKC), extracellular signal-regulated kinase (ERK), transforming growth factor (TGF)-ß1, and angiotensin II.3-5 The pathological characteristics of diabetic nephropathy are the thickness of the basement membrane and mesangial expansion in glomeruli, followed by glomerular sclerosis and a decrease in renal function.5,6

Midkine (MK) is a heparin-binding growth factor that was first discovered as the product of a retinoic acid-responsive gene.7,8 The major biological roles of MK can be categorized into three areas, namely the nervous system, cancer, and inflammation.9 MK supports neuronal cell survival and neurite extension.10,11 The neuronal cytoprotective effect of MK has been demonstrated in various in vivo models, including retinal degeneration induced by constant light exposure,12 cerebral infarction,13 and ischemia-induced neuronal death.14,15 In human carcinomas, MK expression is often elevated and is associated with a poor prognosis. MK antisense oligodeoxynucleotide (ODN) can suppress not only MK expression but also tumor formation.16 In addition, MK is involved in inflammation, as revealed by studies involving MK-deficient (Mdk–/–) mice. Arterial restenosis,17 ischemic reperfusion-induced renal damage,18 cis-platin-induced renal damage,19 and rheumatoid arthritis20 are manifested to a lesser extent in Mdk–/– mice. MK antisense ODN can suppress arterial restenosis,21 ischemic reperfusion-induced renal damage,22 and cis-platin-induced renal damage in Mdk+/+ mice.19

Although MK plays a critical role in the development of inflammation-related, acute renal damage,18,22 its role in chronic renal diseases and glomerular damage, in which inflammation may not play a central role, has been uncertain. In the present study, we found that MK was induced in the glomerular mesangium in diabetic nephropathy. We report here an unexpected, significant difference in diabetic nephropathy between wild-type (Mdk+/+) and MK-deficient (Mdk–/–) mice. This study reveals a novel key molecule in diabetic nephropathy.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Animals and Experimental Design

Mice deficient in the MK gene (Mdk) were generated as described previously.23 After backcrossing of Mdk+/– mice for 14 generations with 129/SV mice, Mdk+/– mice were mated with each other to generate Mdk+/+ and Mdk–/– mice, which were used in this study. Experiments were performed on 8- to 12-week-old female mice weighing 20 to 25 g that were housed under controlled environmental conditions and maintained with standard food and water.

Diabetes mellitus was induced in Mdk+/+ mice and Mdk–/– mice with single intraperitoneal injections of Streptozotocin (STZ; 140 mg/kg body weight; Sigma, St. Louis, MO) on 2 consecutive days. The blood glucose levels were measured weekly after injection of STZ using a glucometer. Mice with blood glucose levels of more than 250 mg/dl were regarded as being in a diabetic state. The levels were maintained between 350 mg/dl and 500 mg/dl within the experimental period. Mice were sacrificed at 2, 4, and 6 months after injection of STZ. Kidneys were removed for examination. Blood and urine samples were collected on the day of sacrifice. Kidney tissues were processed for histology and protein extraction. All of the animal experiments were performed in accordance with the animal experimentation guide of Nagoya University School of Medicine.

Biochemical Examination

Renal function was evaluated by determination of urine-albumin/urine-creatinine, urine-protein/urine-creatinine, and blood urea nitrogen (BUN). Albumin, protein, and creatinine in urine, and BUN were measured using a Mouse Albumin enzyme-linked immunosorbent assay (ELISA) kit (Shibayagi, Gunma, Japan), a micro-TP test kit (Wako, Osaka, Japan), a Cre-Kainos kit (Kainos Co., Ltd., Tokyo, Japan), and an Iatrochrom UN Kit (Iatron Co., Ltd., Tokyo, Japan), respectively.

Morphological Assessment

The removed kidneys were fixed in 4% paraformaldehyde, embedded in paraffin and then cut into 4-µm sections. The sections were stained with periodic acid-Schiff reagent (PAS) and periodic acid-methenamine-silver (PAM). For the morphometric analysis, the extent of glomerular sclerosis was assessed by examining 20 glomeruli cut at their vascular poles in a section. The extent of increase in mesangial matrix was determined by assessing the PAS-positive and nuclei-free area in the mesangium.24,25 The glomerular area was also treated along the outline of capillary loop. Their areas were measured using MetaMorph 6.3 image analysis computer program (Universal Imaging Co., West Chester, PA).26,27

Immunohistochemical Labeling for Type I and IV Collagen, Macrophages, and Midkine

Parts of the kidney tissues were snap-frozen in liquid nitrogen. Sections (4-µm thick) were cut with a cryostat and fixed in acetone. The sections were stained with polyclonal rabbit anti-rat type I collagen (Chemicon International, Temecula, CA) or rabbit anti-bovine type IV collagen (LSL Co., Tokyo, Japan), followed by detection with fluorescein isothiocyanate (FITC) goat anti-rabbit IgG (Zymed Laboratories, San Francisco, CA).

Cryosections were stained with monoclonal rat anti-mouse monocyte-macrophage marker F4/80 (Serotec, Oxford, UK), followed by detection with FITC rabbit anti-rat IgG (Zymed Laboratories). Leukocytes positive for F4/80 were counted by examining 20 glomeruli under a microscope at 400x magnification in a blind manner.18

Tissue sections were pretreated with 0.4% hydrogen peroxide for 20 minutes, followed by avidin and biotin block (Vector Laboratories, Burlingame, CA) and 10% normal rabbit serum for 1 hour to prevent nonspecific detection. Sections were then incubated with chicken anti-human MK overnight at 4°C and biotin-conjugated rabbit anti-chicken IgG (ICN Pharmaceuticals Inc., Aurora, OH) for 1 hour. Immunostaining was performed by the streptavidin (Chemicon International)-biotin immunoperoxidase method. The staining was visualized with 3,3'-diaminobenzidine (Dako, Carpinteria, CA) to produce a brown color.

Cryosections were stained with chicken anti-human MK overnight at 4°C, followed by detection with FITC goat anti-chicken IgG (Zymed Laboratories) for 1 hour. Negative controls were performed by replacing primary antibodies with species-matched antibodies.

Cell Culture

A glomerular mesangial primary culture was established from glomeruli isolated by conventional sieving methods from the kidneys of adult Mdk+/+ or Mdk–/– mice and was identified according to the method previously described.28,29 Mesangial cells between the fourth and sixth passages were plated on 60-mm plastic dishes (Iwai Chemicals, Tokyo, Japan) and maintained in growth medium (3:1 mixture of DMEM:Ham’s F-12 medium supplemented with 1 mmol/L glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, and 20% fetal bovine serum; GIBCO-BRL, Gaithersburg, MD).30 Murine glomerular mesangial cells (MES-13) were obtained from the American Type Culture Collection (Manassas, VA) and maintained in DMEM containing 5.4 mmol/L D-glucose supplemented with 5% fetal bovine serum. Subconfluent mesangial cells were incubated in serum-free medium for 24 hours to arrest and synchronize cell growth. After this period, the medium was changed to fresh serum-free DMEM containing 25 mmol/L D-glucose (Sigma) or DMEM containing 5.4 mmol/L D-glucose (Sigma) for 0, 3, 6, 12, or 24 hours. GF109203X (Sigma) was used as a PKC inhibitor to confirm the relationship between MK and PKC. In another experiment, cells were also exposed to 25 mmol/L D-glucose medium in the presence of 100 ng/ml human recombinant MK for 0, 3, 6, 12, or 24 hours.31 Cells were then lysed in RIPA buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1% Nonidet P-40, 1% deoxycolic acid, and 0.05% sodium dodecyl sulfate) containing 0.25 mmol/L phenylmethylsulfonyl fluoride, kept on ice for 60 minutes, and then centrifuged at 15,000 x g for 10 minutes at 4°C. The supernatants were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting.

Western Blot Analysis

Mouse kidney tissues were snap-frozen in liquid nitrogen for protein isolation. Western blot analysis was performed as described previously.32 The blots were subsequently incubated with rabbit anti-MK antibody, monoclonal anti-ß-actin antibody (Sigma-Aldrich, St. Louis, MO), rabbit anti-phospho-p44/42 mitogen-activated protein (MAP) kinase polyclonal antibody, rabbit anti-phospho-protein kinase C (pan) antibody (Cell Signaling Technology, Beverly, MA), or mouse anti-pan-ERK (Transdaction Laboratories, Lexington, KY), followed by incubation with peroxidase-conjugated rabbit IgG and mouse IgG (Jackson Immunoresearch Laboratories Inc., West Grove, PA). Proteins were visualized with an enhanced chemiluminescence detection system (Amersham Pharmacia, Amersham Biosciences, Piscataway, NJ). The density of each band was measured using the public domain NIH Image program.

TGF-ß1 Protein ELISA Assay

After cell growth had been synchronized, subconfluent mesangial cells were incubated in fresh DMEM containing 25 mmol/L D-glucose and 0.5% fetal bovine serum. Cell culture supernatants were collected after a certain time, and TGF-ß1 levels were measured using an ELISA kit (R&D Systems, Minneapolis, MN), according to the manufacturer’s instructions. The results were normalized as to the total protein concentration.

In Vitro Administration of Antisense ODN Targeted to MK

MES-13 cells were transfected with mouse MK antisense or scramble ODN as described previously.16,22 After 48 hours of incubation in serum-free DMEM containing 25 mmol/L D-glucose, conditioned medium was collected for analysis of MK expression, and a cell lysate was used for evaluation of phosphorylated ERK 1/2.

Statistical Analysis

All values are expressed as means ± SEM. Statistical analysis was performed with unpaired, two-tailed Student’s t-test for single comparisons or analysis of variance for multiple comparisons. A P value of <0.05 was taken to indicate a significant difference.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Body Weight and Blood Glucose Levels

To develop a mouse model of diabetes mellitus, we injected STZ into Mdk+/+ or Mdk–/– mice with the 129sv background. Insulin treatment was not performed. Blood glucose was markedly increased 2 months after STZ administration (Table 1) . There was not an apparent body weight loss (Table 1) . There were no significant differences in body weight and blood glucose levels between Mdk+/+ and Mdk–/– mice (Table 1) .


View this table:
[in this window]
[in a new window]
  		Table 1. Blood Glucose and Body Weight in Mdk+/+ and Mdk–/– Mice

 
Glomerular Sclerosis Is Less Marked in MK-Deficient Mice

To determine the role of MK in the chronic phase of diabetic nephropathy in vivo, we compared the degrees of glomerular sclerosis in Mdk+/+ and Mdk–/– mice. No obvious mesangial expansion was observed by light microscopy in either genotype a month after STZ injection, although the glomerulus became hypertrophic (data not shown). At 2 months after STZ injection, Mdk+/+ mice exhibited a diffuse increase in PAS-positive materials in the mesangial areas (Figure 1A, b) , which became more diffuse and severe at 4 months (Figure 1A, c) . At 6 months, the glomeruli of Mdk+/+ mice showed diabetic nodular lesions (Figure 1A, d) , as demonstrated by thickening of the glomerular basement membrane of the peripheral capillary loops and the lobular formation of diabetic nodular lesions observed on PAM staining (Figure 1B, a) . By contrast, Mdk–/– mice showed only a few PAM-positive areas at 6 months (Figure 1B, b) . After 4 months, the glomeruli of Mdk+/+ mice were gradually reduced in size and finally became obsolescent glomeruli (Figure 1A, d) . It is of note that the increase in the mesangial matrix was not associated with an increase in the number of nuclei (Figure 1) . Overall, the histological features of Mdk+/+ mice indicated severe glomerular sclerosis. Diffuse obsolescent glomeruli were found 1 year after STZ injection in Mdk+/+ mice (data not shown).



View larger version (63K):
[in this window]
[in a new window]
  		Figure 1. Glomerular histology of STZ-induced nephropathy in Mdk+/+ and Mdk–/– mice. A: A glomerulus at 0, 2, 4, and 6 months, respectively, is shown by PAS staining. a–d: Mdk+/+ mice; e–h: Mdk–/– mice. Bar = 50 µm. B: A glomerulus at 6 months is shown by PAM staining. a: Mdk+/+ mice; b: Mdk–/– mice. Bar = 50 µm.

 
The histological observation shown in Figure 1A was further evaluated quantitatively with the aid of an image analysis program. Glomerular area of Mdk–/– mice increased with age, whereas that of Mdk+/+ mice transiently increased at 2 months and then decreased afterward (Figure 2A) . Mesangial area and mesangiumto-glomeruli ratio increased in both genotypes but significantly more in Mdk+/+ than Mdk–/– mice (Figure 2, B and C) .



View larger version (18K):
[in this window]
[in a new window]
  		Figure 2. Morphometric analysis of glomerular pathology in Mdk+/+ and Mdk–/– mice. A: Glomerular area (µm2). B: Mesangial area (µm2). C: Mesangial area/glomerular area. Data are shown as means (columns) and SEM (bars). {square}, Mdk+/+ mice; {blacksquare}, Mdk–/– mice. *P < 0.0001; **P < 0.005. n = 12.

 
Renal Function

Renal function was then evaluated by means of urine-albumin/urine-creatinine, urine-protein/urine-creatinine and BUN values. Both microalbuminuria, which is a hallmark of glomerular hyperfiltration, and overt proteinuria are good predictors of the development of diabetic nephropathy. Both genotypes showed microalbuminuria to a similar extent at 2 weeks, but microalbuminuria of Mdk+/+ mice strikingly increased after 4 weeks (Figure 3A) . Consequently, microalbuminurea was significantly more severe in Mdk+/+ than Mdk–/– mice between 4 and 8 weeks (Figure 3A) . Proteinurea became apparent from 2 months in both genotypes; the levels were much higher in Mdk+/+ than Mdk–/– mice (Figure 3B) . BUN gradually increased toward 6 months in both genotypes. Mdk+/+ mice showed significantly higher BUN levels than Mdk–/– mice after 4 months (Figure 3C) .



View larger version (17K):
[in this window]
[in a new window]
  		Figure 3. Renal function in STZ-treated Mdk+/+ and Mdk–/– mice. A: Urine-albumin/urine-creatinine. Urinary albumin was measured at 0, 2, 4, 6, and 8 weeks. *P < 0.05. n = 5. B: Urine-protein/urine-creatinine. *P < 0.001. n = 12. C: Blood urea nitrogen. Data are means ± SEM. {square}, Mdk+/+ mice; {blacksquare}, Mdk–/– mice. *P < 0.001. n = 12.

 
The Accumulation of Type I and IV Collagen

Type I and IV collagens are the PAS-positive materials in the mesangial area, and deposition of them is a hallmark of glomerular sclerosis. Both type I and IV collagen-stained areas increased in Mdk+/+ and Mdk–/– mice at 4 and 6 months, but to higher extents in Mdk+/+ mice (Figure 4) .



View larger version (50K):
[in this window]
[in a new window]
  		Figure 4. Immunohistochemical analysis of ECM accumulation in STZ-treated Mdk+/+ and Mdk–/– mice. Immunofluorescence staining for type I collagen (A) and type IV collagen (B). Bar = 50 µm.

 
MK Expression during the Development of Glomerular Sclerosis

We next addressed whether MK expression was increased in vivo, particularly in the glomerulus, during the pathogenesis of diabetic nephropathy. Strong staining of MK protein in the glomerulus was detected in the Mdk+/+ mice treated with STZ (Figure 5, A and B) . MK staining became apparent at 2 months (Figure 5A (b) and 5B (b)), and nodular and stronger at 4 and 6 months (Figure 5A, c and d) . The overall profile was reminiscent of those of PAS staining and collagen I and IV deposition (Figures 1 and 4) . In addition to changes in the glomerulus, increase of MK expression was also observed in tubules at 4 months (Figure 5C) .



View larger version (76K):
[in this window]
[in a new window]
  		Figure 5. MK expression in glomeruli and tubulointerstitium of STZ-treated Mdk+/+ mice. A: Immunohistochemical staining of glomeruli is shown. a: Pre-injection; b: 2 months; c: 4 months; d: 6 months. B: Immunofluorescence staining of glomeruli. a: Pre-injection; b: 2 months. C: Immunohistochemical staining of tubulointerstitium. a: Pre-injection; b: 4 months. Bar = 50 µm.

 
We then attempted to determine the direct effect of glucose on MK expression in the glomerulus. Exposure of primary cultured mesangial cells from Mdk+/+ mice to 25 mmol/L D-glucose led to a significant increase in the cellular expression of MK protein, which reached the maximum level at 6 hours (Figure 6, A and B) . MK expression was similarly enhanced in the mesangial cell line MES-13 when exposed to 25 mmol/L D-glucose (Figure 6C) . D-Glucose, but not the enantiomer L-glucose, acts as an energy source and causes diabetes mellitus if present at high concentrations. Therefore, L-glucose can be used as a negative control for "high glucose" loading. Cells exposed to 25 mmol/L L-glucose did not show a marked increase in MK expression (Figure 6, A and D) , suggesting that MK induction is due to D-glucose rather than high osmotic pressure.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 6. MK expression in cultured mesangial cells from Mdk+/+ mice. A: Time course of MK expression in cultured mesangial cells on exposure to 25 mmol/L D-glucose or L-glucose. MK protein was determined by Western blotting. B: The intensity of MK bands obtained from D-glucose treatment in A was normalized as to ß-actin. Data are means ± SEM for three independent experiments. *P < 0.05. C: Time course of MK expression in MES-13 cells on exposure to 25 mmol/L D-glucose. D: MK expression in cultured mesangial cells on exposure to 25 mmol/L D-glucose, 25 mmol/L L-glucose, or 5.4 mmol/L D-glucose for 6 hours. The intensity of MK bands was normalized as to ß-actin. Data are means ± SEM for three independent experiments. *P < 0.05 versus 5.4 mmol/L D-glucose.

 
PKC and MAP Kinase Pathways

High glucose significantly increased the phosphorylation of PKC in mesangial cells, which was maximal at 6 hours after treatment (Figure 7, A and B) . Mesangial cells from Mdk+/+ mice responded to high glucose more strikingly than those from Mdk–/– mice (Figure 7, A and B) . It is of note that MK expression and the phosphorylation of PKC showed similar profiles after high glucose treatment in Mdk+/+ mice (Figures 6B and 7B) . However, 10 µmol/L GF109203X, a PKC inhibitor, did not affect MK expression (Figure 7C) .



View larger version (23K):
[in this window]
[in a new window]
  		Figure 7. Comparison of glucose-induced signal pathways in cultured Mdk+/+ and Mdk–/– mesangial cells. A: Cultured Mdk+/+ and Mdk–/– mesangial cells were examined for the expression of phosphorylated PKC after 25 mmol/L D-glucose exposure. B: The intensity of phospho-PKC bands in A was normalized as to ß-actin. Data are means ± SEM for three independent experiments. *P < 0.01; **P < 0.001. #P < 0.0001 versus Mdk+/+ mesangial cells at 0 hour. {square}, Mdk+/+; {blacksquare}, Mdk–/–. C: Cultured mesangial cells were examined for the expression of phosphorylated PKC and MK after 6 hours exposure to 25 mmol/L D-glucose and 10 µmol/L GF109203X. D: The phosphorylation of ERK 1/2 (p44/42 MAP kinase) was examined in cultured mesangial cells from Mdk+/+ mice after 25 mmol/L D-glucose exposure. E: The quantitative results in D were expressed as the relative ratio of phosphorylated to pan-ERK. Data are means ± SEM for three independent experiments. {square}, Mdk+/+; {blacksquare}, Mdk–/–. *P < 0.001; **P < 0.0001. #P < 0.001 versus Mdk+/+ mesangial cells at 0 hour.

 
Phosphorylation of ERK in mesangial cells decreased transiently and then significantly increased after exposure to high glucose (Figure 7, D and E) . The phosphorylation after treatment was significantly higher at 6, 12, and 24 hours in mesangial cells from Mdk+/+ mice than in ones from Mdk–/– mice (Figure 7, D and E) . L-Glucose (25 mmol/L) and D-glucose (5.4 mmol/L) had no effect on the phosphorylation of ERK 1/2 or PKC (data not shown).

To determine whether the difference in ERK phosphorylation between Mdk+/+ and Mdk–/– mice is due to the presence or absence of MK, we next examined the effect of MK protein on Mdk–/– mesangial cells. In Mdk–/– mesangial cells exposed to 25 mmol/L D-glucose in the presence of 100 ng/ml MK, ERK 1/2 phosphorylation was induced with a profile similar to that in Mdk+/+ cells exposed to 25 mmol/L D-glucose (Figure 8, A and B) . Importantly, exogenous MK protein administration together with high glucose had no effect on PKC phosphorylation in Mdk–/– mesangial cells (data not shown). To further confirm the importance of MK in ERK phosphorylation, MES-13 cells were transfected with MK antisense ODN and then exposed to 25 mmol/L D-glucose. As shown in Figure 8, C and D , MK antisense but not control scramble ODN significantly suppressed MK production and simultaneously ERK phosphorylation.



View larger version (25K):
[in this window]
[in a new window]
  		Figure 8. Effect of MK on the phosphorylation of ERK 1/2 in cultured mesangial cells from Mdk–/– mice and MES-13 cells under high glucose conditions. A: Phosphorylated ERK expression in Mdk–/– mesangial cells exposed to 100 ng/ml MK was almost equal to that in Mdk+/+ under high glucose conditions. B: The phosphorylated/pan-ERK ratios in A are shown. The results are means ± SEM for four independent experiments. *P < 0.0001 versus Mdk–/– without MK exposure at each time point under high glucose conditions. {square}, Mdk+/+; {blacksquare}, Mdk–/–. C: MES-13 cells were transfected with antisense or scramble ODN and then examined for the expression of phospho-ERK 1/2 after 24 hours exposure to 25 mmol/L D-glucose. AS, MK antisense ODN; Scr, MK scramble ODN; NT, no treatment. D: The intensity of phospho-ERK 1/2 bands in A was normalized as to pan ERK. Data are means ± SEM for three independent experiments. *P < 0.01 versus MK scramble ODN.

 
TGF-ß1 Expression

TGF-ß1 plays an important role in the progression of diabetic nephropathy. TGF-ß1 stimulates extracellular matrix synthesis in mesangial cells through the up-regulation of phosphorylated ERK 1/2. To further prove the importance of MK in this model, we verified TGF-ß1 expression in Mdk+/+ or Mdk–/– mesangial cells exposed to 25 mmol/L D-glucose. ELISA assaying revealed that there was no obvious difference in TGF-ß1 expression between Mdk+/+ and Mdk–/– cells on days 1 and 2, but it was significantly increased more in Mdk+/+ cells than in Mdk–/– cells on days 3 and 4 (Figure 9) .



View larger version (20K):
[in this window]
[in a new window]
  		Figure 9. TGF-ß1 expression in Mdk+/+ or Mdk–/– mesangial cells under high glucose conditions. TGF-ß1 was measured by ELISA. Data are means ± SEM for five independent experiments. {square}, Mdk+/+; {blacksquare}, Mdk–/–. *P < 0.05; **P < 0.01.

 
Macrophage Infiltration into Glomeruli

Finally, we examined macrophage infiltration. Macrophage infiltration is another key event during the pathogenesis of diabetic nephropathy. Macrophage infiltration into glomeruli was more significant in Mdk+/+ mice than Mdk–/– mice, the maximum level being reached at 2 months (Figure 10) .



View larger version (37K):
[in this window]
[in a new window]
  		Figure 10. Macrophage infiltration in STZ-treated Mdk+/+ and Mdk–/– mice. A: Immunofluorescence staining with F4/80 antibody of glomeruli at 2 months. a: Mdk+/+ mice; b: Mdk–/– mice. Arrows indicate some of the positively stained cells. Bar = 50 µm. B: The numbers of macrophages that had infiltrated into the glomeruli at 2 and 4 months were determined. They were scored by examining 20 glomeruli under a microscope at 400x magnification. Data are means ± SEM. {square}, Mdk+/+; {blacksquare}, Mdk–/–. *P < 0.01. n = 12.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
Maintenance of normoglycemia by treatment such as pancreas transplantation can induce regression of glomerular pathological changes.33 Several cohort studies have also clearly linked longstanding hyperglycemia to diabetic nephropathy.34-36 Therefore, understanding of the molecular events evoked by hyperglycemia is important for therapeutic strategies for diabetic nephropathy. Among such molecular events, activation of ERK is a critical one. Thus, ERK phosphorylation is linked to overproduction of TGF-ß, which is considered to be the final mediator of ECM accumulation and hyperfiltration in this disease.3-5 We demonstrated here that MK is induced by high glucose. ERK phosphorylation on high glucose is less in Mdk–/– mesangial cells and is enhanced by the combination of high glucose and exogenous MK. MK knockdown reduces ERK phosphorylation. Our data strongly suggest that MK accelerates the intracellular signaling network, particularly via ERK activation, evoked by longstanding hyperglycemia.

Because high glucose activates PKC and ERK and the general PKC inhibitor calphostin C can prevent ERK activation with high glucose,3-5,37 ERK and PKC are thought to be tightly associated. We demonstrated here that the combination of exogenous MK and high glucose only induces ERK phosphorylation, ie, not PKC phosphorylation, in Mdk–/– mesangial cells. Our data indicate that MK is necessary but not sufficient for PKC activation, whereas it is necessary and sufficient for ERK phosphorylation. Therefore, this study provides a model for the study of molecular mechanisms differentiating these two general intracellular signaling molecules. Supporting our study, it has been reported that p8 is activated under the control of ERK and plays a critical role in mesangial hypertrophy.38

Based on the present data, we are currently considering the molecular network in diabetic nephropathy, as illustrated in Figure 11 . Besides PKC, ERK, and TGF-ß, the infiltration of macrophages into the glomerulus is critical in the early phase of the pathogenesis of diabetic nephropathy.39,40 MK may also contribute to the macrophage infiltration in this disease. This idea is supported by data that the glomerular infiltration of macrophages was reduced in Mdk–/– mice in diabetic nephropathy. Induction of macrophage infiltration by MK has been established in several in vivo and in vitro models.17,18,20,41 In addition, induction of MK expression in renal tubules in our study suggest that pathological changes in the interstitium and tubule also contribute to the pathogenesis of diabetic nephropathy.



View larger version (15K):
[in this window]
[in a new window]
  		Figure 11. Schematic diagram showing the possible relationship between MK- and glucose-induced signaling pathways that promote glomerular sclerosis.

 
There are currently ongoing phase 3 clinical trials with a PKC inhibitor. However, one should be very careful about adverse effects because ERK and PKC are general signaling molecules. In this context, it is of note that MK is expressed at low levels in adult tissues and only induced in some pathological conditions, such as carcinogenesis,42-44 inflammation,17-20,41 and diabetic nephropathy. Thus, MK is an intriguing candidate molecular target for a therapy for diabetic nephropathy. Several knockdown studies, involving such as treatment of carcinomas,16 arterial restenosis,21 and reperfusion renal injury,22 demonstrated that MK could be an appropriate target without apparent adverse effects.

Several models of diabetic nephropathy have been reported.4,24-27,45 However, in most cases, it is hard to obtain glomerular sclerosis even when hyperglycemia has been achieved. We thus considered the effects of the genetic backgrounds of the mouse strains used. As to glomerular sclerosis, a report has demonstrated that 129/SV is prone to glomerular sclerosis compared with C57BL/6J in a 5/6 kidney removal model.46 In the present study, we succeeded in establishing glomerular sclerosis after hyperglycemia induced by injection of STZ. Our model will be useful for further study on the molecular mechanisms underlying diabetic nephropathy.


   Acknowledgements
 
We thank N. Suzuki, N. Asano, T. Katahara, and Y. Sawa for their excellent technical assistance and H. Inoue and T. Adachi for secretarial assistance.


   Footnotes
 
Address reprint requests to Kenji Kadomatsu, Department of Biochemistry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: kkadoma{at}med.nagoya-u.ac.jp

Supported by grants-in-aid from the Ministry of Education, Science, Sports, and Culture of Japan (14580647 to K.K.; 15390103 to T.M.; 15590849 to Y.Y.).

Accepted for publication September 6, 2005.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J: Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994, 330:15-18[Abstract/Free Full Text]
  2. Krolewski M, Eggers PW, Warram JH: Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 1996, 50:2041-2046[Medline]
  3. Gunter W, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999, 56:393-405[CrossRef][Medline]
  4. Mason RM, Wahab NA: Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003, 14:1358-1373[Abstract/Free Full Text]
  5. Haneda M, Koya D, Isono M, Kikkawa R: Overview of glucose signal-ing in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 2003, 14:1374-1382[Free Full Text]
  6. Ziyadeh FN: The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993, 22:736-744[Medline]
  7. Kadomatsu K, Tomomura M, Muramatsu T: cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988, 151:1312-1318[CrossRef][Medline]
  8. Tomomura M, Kadomatsu K, Matsubara S, Muramatsu T: A retinoic acid-responsive gene MK, found in the teratocarcinoma system: heterogeneity of the transcript and the nature of the translation product. J Biol Chem 1990, 265:10765-10770[Abstract/Free Full Text]
  9. Kadomatsu K, Muramatsu T: Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004, 204:127-143[CrossRef][Medline]
  10. Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, Muramatsu T, Michikawa M: Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem 1999, 73:2084-2092[Medline]
  11. Muramatsu H, Shirahama H, Yonezawa S, Maruta H, Muramatsu T: Midkine, a retinoic acid-inducible growth/differentiation factor: immunochemical evidence for the function and distribution. Dev Biol 1993, 159:392-402[CrossRef][Medline]
  12. Unoki K, Ohba N, Arimura H, Muramatsu H, Muramatsu T: Rescue of photoreceptors from the damaging effects of constant light by midkine, a retinoic acid-responsive gene product. Invest Ophthalmol Vis Sci 1994, 35:4063-4068[Abstract/Free Full Text]
  13. Yoshida Y, Goto M, Tsutsui J, Ozawa M, Sato E, Osame M, Muramatsu T: Midkine is present in the early stage of cerebral infarct. Brain Res Dev Brain Res 1995, 85:25-30[Medline]
  14. Yoshida Y, Ikematsu S, Moritoyo T, Goto M, Tsutsui J, Sakuma S, Osame M, Muramatsu T: Intraventricular administration of the neurotrophic factor midkine ameliorates hippocampal delayed neuronal death following transient forebrain ischemia in gerbils. Brain Res 2001, 894:46-55[CrossRef][Medline]
  15. Takada J, Ooboshi H, Ago T, Kitazono T, Yao H, Kadomatsu K, Muramatsu T, Ibayashi S, Iida M: Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia. Gene Ther 2005, 12:487-493[CrossRef][Medline]
  16. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, Muramatsu T: Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001, 61:8486-8491[Abstract/Free Full Text]
  17. Horiba M, Kadomatsu K, Nakamura E, Muramatsu H, Ikematsu S, Sakuma S, Hayashi K, Yuzawa Y, Matsuo S, Kuzuya M, Kaname T, Hirai M, Saito H, Muramatsu T: Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 2000, 105:489-495[Medline]
  18. Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S, Muramatsu T: Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 2001, 167:3463-3469[Abstract/Free Full Text]
  19. Kawai H, Sato W, Yuzawa Y, Kosugi T, Matsuo S, Takei Y, Kadomatsu K, Muramatsu T: Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage. Am J Pathol 2004, 165:1603-1612[Abstract/Free Full Text]
  20. Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T: Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004, 50:1420-1429[CrossRef][Medline]
  21. Hayashi K, Banno H, Kadomatsu K, Takei Y, Komori K, Muramatsu T: Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury. Am J Physiol Heart Circ Physiol 2005, 288:H2203-H2209[Abstract/Free Full Text]
  22. Sato W, Takei Y, Yuzawa Y, Matsuo S, Kadomatsu K, Muramatsu T: Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion. Kidney Int 2005, 67:1330-1339[CrossRef][Medline]
  23. Nakamura E, Kadomatsu K, Yuasa S, Muramatsu H, Mamiya T, Nabeshima T, Fan QW, Ishiguro K, Igakura T, Matsubara S, Kaname T, Horiba M, Saito H, Muramatsu T: Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Genes Cells 1998, 3:811-822[Abstract]
  24. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC ß inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000, 14:439-447[Abstract/Free Full Text]
  25. Chin M, Isono M, Isshiki K, Araki S, Sugimoto T, Guo B, Sato H, Haneda M, Kashiwagi A, Koya D: Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol 2005, 166:1629-1636[Abstract/Free Full Text]
  26. Zheng F, Plati AR, Potier M, Schulman Y, Berho M, Banerjee A, Leclercq B, Zisman A, Striker LJ, Striker GE: Resistance to glomerulosclerosis in B6 mice disappears after menopause. Am J Pathol 2003, 162:1339-1348[Abstract/Free Full Text]
  27. Elliot SJ, Karl M, Berho M, Potier M, Zheng F, Leclercq B, Striker GE, Striker LJ: Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am J Pathol 2003, 162:1441-1448[Abstract/Free Full Text]
  28. MacKay K, Striker LJ, Elliot S, Pinkert CA, Brinster RL, Striker GE: Glomerular epithelial, mesangial, and endothelial cell lines from transgenic mice. Kidney Int 1988, 33:677-684[Medline]
  29. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ: Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992, 89:2873-2877[Abstract/Free Full Text]
  30. Nagai K, Arai H, Yanagita M, Matsubara T, Kanamori H, Nakano T, Iehara N, Fukatsu A, Kita T, Doi T: Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem 2003, 278:18229-18234[Abstract/Free Full Text]
  31. Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M, Muramatsu T, Kadomatsu K: Haptotactic migration induced by midkine. J Biol Chem 2001, 276:15868-15875[Abstract/Free Full Text]
  32. Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, Muramatsu T: Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997, 75:354-359[Medline]
  33. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75[Abstract/Free Full Text]
  34. : The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986[Abstract/Free Full Text]
  35. Ohkubo Y, Kishikawa H, Arai E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117[CrossRef][Medline]
  36. : UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352:837-853[CrossRef][Medline]
  37. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R: Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997, 46:847-853[Abstract]
  38. Goruppi S, Bonventre JV, Kyriakis JM: Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 2002, 21:5427-5436[CrossRef][Medline]
  39. Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel O, Perdereau B, Bariety J, Bruneval P: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 2000, 49:466-475[Abstract]
  40. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003, 52:2586-2593[Abstract/Free Full Text]
  41. Inoh K, Muramatsu H, Ochiai K, Torii S, Muramatsu T: Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions. Biochem Biophys Res Commun 2004, 317:108-113[CrossRef][Medline]
  42. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, Shimazu H, Ohi Y, Muramatsu T: A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumor and other human carcinomas. Cancer Res 1993, 53:1281-1285[Abstract/Free Full Text]
  43. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur GM: Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 1995, 55:1792-1797[Abstract/Free Full Text]
  44. O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996, 56:2515-2518[Abstract/Free Full Text]
  45. Zheng F, Striker GE, Esposito C, Lupia E, Striker LJ: Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int 1998, 54:1999-2007[CrossRef][Medline]
  46. Ma LJ, Fogo AB: Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 2003, 64:350-355[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
T. Ozaki, C. Anas, S. Maruyama, T. Yamamoto, K. Yasuda, Y. Morita, Y. Ito, M. Gotoh, Y. Yuzawa, and S. Matsuo
Intrarenal administration of recombinant human soluble thrombomodulin ameliorates ischaemic acute renal failure
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 110 - 119.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
T. Nakagawa, W. Sato, O. Glushakova, M. Heinig, T. Clarke, M. Campbell-Thompson, Y. Yuzawa, M. A. Atkinson, R. J. Johnson, and B. Croker
Diabetic Endothelial Nitric Oxide Synthase Knockout Mice Develop Advanced Diabetic Nephropathy
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 539 - 550.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kosugi, T.
Right arrow Articles by Kadomatsu, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kosugi, T.
Right arrow Articles by Kadomatsu, K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS